Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 191

1.

Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells.

Krug S, Mordhorst JP, Moser F, Theuerkorn K, Ruffert C, Egidi M, Rinke A, Gress TM, Michl P.

PLoS One. 2019 Jun 25;14(6):e0218953. doi: 10.1371/journal.pone.0218953. eCollection 2019.

2.

Testing of Helicobacter pylori by Endoscopic Biopsy: The Clinical Dilemma of Suppressive Conditions.

Knoop RF, Petzold G, Amanzada A, Bremer SCB, Gress TM, Ellenrieder V, Neesse A, Kunsch S.

Digestion. 2019 Jun 19:1-5. doi: 10.1159/000501270. [Epub ahead of print]

PMID:
31216545
3.

Controversies on the endoscopic and surgical management of pain in patients with chronic pancreatitis: pros and cons!

Drewes AM, Kempeneers MA, Andersen DK, Arendt-Nielsen L, Besselink MG, Boermeester MA, Bouwense S, Bruno M, Freeman M, Gress TM, van Hooft JE, Morlion B, Olesen SS, van Santvoort H, Singh V, Windsor J.

Gut. 2019 Aug;68(8):1343-1351. doi: 10.1136/gutjnl-2019-318742. Epub 2019 May 25. No abstract available.

4.

Recent survival trends in high-grade neuroendocrine neoplasms and lung cancer.

Breitling LP, Rinke A, Gress TM.

Neuroendocrinology. 2019 May 13. doi: 10.1159/000500883. [Epub ahead of print]

PMID:
31079108
5.

PLAC8 is overexpressed and regulates cell proliferation in low-grade human PanNET.

Tatura M, Schmidt H, Haijat M, Stark M, Rinke A, Diels R, Lawlor R, Scarpa A, Schrader J, Hackert T, Schimmack S, Gress TM, Buchholz M.

Neuroendocrinology. 2019 Apr 25. doi: 10.1159/000500541. [Epub ahead of print]

PMID:
31018208
6.

Brain metastases in patients with neuroendocrine neoplasms: risk factors and outcome.

Krug S, Teupe F, Michl P, Gress TM, Rinke A.

BMC Cancer. 2019 Apr 16;19(1):362. doi: 10.1186/s12885-019-5559-7.

7.

[Pancreatic neuroendocrine tumors : Current treatment concepts].

Rinke A, Gress TM.

Internist (Berl). 2019 Mar;60(3):247-256. doi: 10.1007/s00108-018-0545-8. Review. German.

PMID:
30623195
8.

High Prevalence of Pathological Hydrogen Breath Tests in Patients with Functional Dyspepsia.

Petzold G, Amanzada A, Gress TM, Ellenrieder V, Neesse A, Kunsch S.

Digestion. 2018 Nov 14:1-6. doi: 10.1159/000494718. [Epub ahead of print]

PMID:
30428469
9.

DYRK1B regulates Hedgehog-induced microtubule acetylation.

Singh R, Holz PS, Roth K, Hupfer A, Meissner W, Müller R, Buchholz M, Gress TM, Elsässer HP, Jacob R, Lauth M.

Cell Mol Life Sci. 2019 Jan;76(1):193-207. doi: 10.1007/s00018-018-2942-5. Epub 2018 Oct 13.

PMID:
30317528
10.

Inactivation of PRIM1 Function Sensitizes Cancer Cells to ATR and CHK1 Inhibitors.

Job A, Schmitt LM, von Wenserski L, Lankat-Buttgereit B, Gress TM, Buchholz M, Gallmeier E.

Neoplasia. 2018 Nov;20(11):1135-1143. doi: 10.1016/j.neo.2018.08.009. Epub 2018 Sep 23.

11.

Stromal biology and therapy in pancreatic cancer: ready for clinical translation?

Neesse A, Bauer CA, Öhlund D, Lauth M, Buchholz M, Michl P, Tuveson DA, Gress TM.

Gut. 2019 Jan;68(1):159-171. doi: 10.1136/gutjnl-2018-316451. Epub 2018 Sep 3. Review.

PMID:
30177543
12.

[Pancreatic ductal adenocarcinoma].

Gallmeier E, Gress TM.

Internist (Berl). 2018 Aug;59(8):805-822. doi: 10.1007/s00108-018-0460-z. German.

PMID:
29980819
13.

[Practice guideline neuroendocrine tumors - AWMF-Reg. 021-27].

Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS); Netzwerk Neuroendokrine Tumoren (NeT) e.V. (Patientenvertretung); Bundesorganisation Selbsthilfe NeuroEndokrine Tumoren e.V. (NET-sgh) (Patientenvertretung); Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V. (DGHO), und Arbeitsgemeinschaft Internistische Onkologie (AIO) der Deutschen Krebsgesellschaft e.V; Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie e.V. (DGAV); Deutsche Gesellschaft für Chirurgie (DGCH); Deutsche Gesellschaft für Endoskopie und Bildgebende Verfahren (DGEBV); Deutsche Gesellschaft für Nuklearmedizin e.V. (DGNM); Deutsche Gesellschaft für Innere Medizin (DGIM); Deutsche Gesellschaft für Endokrinologie (DGE); Deutsche Gesellschaft für Palliativmedizin e.V. (DGP); Deutsche Röntgengesellschaft e.V. (DRG); Deutsche Gesellschaft für Pathologie e.V./Bundesverband Deutscher Pathologen (DGP/BDP); Deutsche Gesellschaft für interventionelle Radiologie (DGiR); Authors; Collaborators:.

Z Gastroenterol. 2018 Jun;56(6):583-681. doi: 10.1055/a-0604-2924. Epub 2018 Jun 11. German.

14.

TGF-β induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression.

Ottaviani S, Stebbing J, Frampton AE, Zagorac S, Krell J, de Giorgio A, Trabulo SM, Nguyen VTM, Magnani L, Feng H, Giovannetti E, Funel N, Gress TM, Jiao LR, Lombardo Y, Lemoine NR, Heeschen C, Castellano L.

Nat Commun. 2018 May 10;9(1):1845. doi: 10.1038/s41467-018-03962-x.

15.

Therapeutic targeting of tumor-associated macrophages in pancreatic neuroendocrine tumors.

Krug S, Abbassi R, Griesmann H, Sipos B, Wiese D, Rexin P, Blank A, Perren A, Haybaeck J, Hüttelmaier S, Rinke A, Gress TM, Michl P.

Int J Cancer. 2018 Oct 1;143(7):1806-1816. doi: 10.1002/ijc.31562.

16.

European evidence-based guidelines on pancreatic cystic neoplasms.

European Study Group on Cystic Tumours of the Pancreas.

Gut. 2018 May;67(5):789-804. doi: 10.1136/gutjnl-2018-316027. Epub 2018 Mar 24.

17.

Smoking and bone mineral density: comprehensive analyses of the third National Health and Nutrition Examination Survey (NHANES III).

Strozyk D, Gress TM, Breitling LP.

Arch Osteoporos. 2018 Mar 3;13(1):16. doi: 10.1007/s11657-018-0426-8.

PMID:
29502242
18.

Combined microRNA and mRNA microfluidic TaqMan array cards for the diagnosis of malignancy of multiple types of pancreatico-biliary tumors in fine-needle aspiration material.

Gress TM, Lausser L, Schirra LR, Ortmüller L, Diels R, Kong B, Michalski CW, Hackert T, Strobel O, Giese NA, Schenk M, Lawlor RT, Scarpa A, Kestler HA, Buchholz M.

Oncotarget. 2017 Nov 21;8(64):108223-108237. doi: 10.18632/oncotarget.22601. eCollection 2017 Dec 8.

19.

Clinicopathological hallmarks and biomarkers of colorectal neuroendocrine neoplasms.

Koenig A, Krug S, Mueller D, Barth PJ, Koenig U, Scharf M, Ellenrieder V, Michl P, Moll R, Homayunfar K, Kann PH, Stroebel P, Gress TM, Rinke A.

PLoS One. 2017 Dec 12;12(12):e0188876. doi: 10.1371/journal.pone.0188876. eCollection 2017.

20.

The deubiquitinating enzyme USP5 promotes pancreatic cancer via modulating cell cycle regulators.

Kaistha BP, Krattenmacher A, Fredebohm J, Schmidt H, Behrens D, Widder M, Hackert T, Strobel O, Hoheisel JD, Gress TM, Buchholz M.

Oncotarget. 2017 Aug 3;8(39):66215-66225. doi: 10.18632/oncotarget.19882. eCollection 2017 Sep 12.

21.

The Role of Cytotoxic Chemotherapy in Advanced Pancreatic Neuroendocrine Tumors.

Krug S, Gress TM, Michl P, Rinke A.

Digestion. 2017;96(2):67-75. doi: 10.1159/000477800. Epub 2017 Jul 21. Review.

22.

Impact of Therapy Sequence with Alkylating Agents and MGMT Status in Patients with Advanced Neuroendocrine Tumors.

Krug S, Boch M, Rexin P, Gress TM, Michl P, Rinke A.

Anticancer Res. 2017 May;37(5):2491-2500.

PMID:
28476818
23.

Functional Imaging in the Follow-Up of Enteropancreatic Neuroendocrine Tumors: Clinical Usefulness and Indications.

Merola E, Pavel ME, Panzuto F, Capurso G, Cicchese N, Rinke A, Gress TM, Iannicelli E, Prosperi D, Pizzichini P, Prasad V, Kump P, Lipp R, Partelli S, Falconi M, Wiedenmann B, Delle Fave G.

J Clin Endocrinol Metab. 2017 May 1;102(5):1486-1494. doi: 10.1210/jc.2016-3732.

PMID:
28324047
24.

Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.

Rinke A, Gress TM.

Digestion. 2017;95(2):109-114. doi: 10.1159/000454761. Epub 2017 Feb 4. Review.

25.

Bone Metastases in Patients with Neuroendocrine Neoplasm: Frequency and Clinical, Therapeutic, and Prognostic Relevance.

Scharf M, Petry V, Daniel H, Rinke A, Gress TM.

Neuroendocrinology. 2018;106(1):30-37. doi: 10.1159/000457954. Epub 2017 Feb 3.

26.

Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer.

Hessmann E, Patzak MS, Klein L, Chen N, Kari V, Ramu I, Bapiro TE, Frese KK, Gopinathan A, Richards FM, Jodrell DI, Verbeke C, Li X, Heuchel R, Löhr JM, Johnsen SA, Gress TM, Ellenrieder V, Neesse A.

Gut. 2018 Mar;67(3):497-507. doi: 10.1136/gutjnl-2016-311954. Epub 2017 Jan 10.

27.

Relevance of dihydropyrimidine-dehydrogenase and thymidylate-synthase in patients with pancreatic neuroendocrine neoplasms treated with 5-FU-based chemotherapy.

Krug S, Boch M, Nimphius W, Gress TM, Michl P, Rinke A.

Pancreatology. 2017 Jan - Feb;17(1):139-145. doi: 10.1016/j.pan.2016.12.006. Epub 2016 Dec 22.

PMID:
28027897
28.

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival.

Rinke A, Wittenberg M, Schade-Brittinger C, Aminossadati B, Ronicke E, Gress TM, Müller HH, Arnold R; PROMID Study Group.

Neuroendocrinology. 2017;104(1):26-32. Epub 2016 Jan 6.

29.

Open Surgical versus Minimal Invasive Necrosectomy of the Pancreas-A Retrospective Multicenter Analysis of the German Pancreatitis Study Group.

Rasch S, Phillip V, Reichel S, Rau B, Zapf C, Rosendahl J, Halm U, Zachäus M, Müller M, Kleger A, Neesse A, Hampe J, Ellrichmann M, Rückert F, Strauß P, Arlt A, Ellenrieder V, Gress TM, Hartwig W, Klar E, Mössner J, Post S, Schmid RM, Seufferlein T, Siech M, Werner J, Will U, Algül H.

PLoS One. 2016 Sep 26;11(9):e0163651. doi: 10.1371/journal.pone.0163651. eCollection 2016.

30.

Low dose DTIC is effective and safe in pretreated patients with well differentiated neuroendocrine tumors.

Mueller D, Krug S, Majumder M, Rinke A, Gress TM.

BMC Cancer. 2016 Aug 18;16:645. doi: 10.1186/s12885-016-2642-1.

31.

miRNA dynamics in tumor-infiltrating myeloid cells modulating tumor progression in pancreatic cancer.

Mühlberg L, Kühnemuth B, Costello E, Shaw V, Sipos B, Huber M, Griesmann H, Krug S, Schober M, Gress TM, Michl P.

Oncoimmunology. 2016 May 9;5(6):e1160181. doi: 10.1080/2162402X.2016.1160181. eCollection 2016 Jun.

32.

Refinement of screening for familial pancreatic cancer.

Bartsch DK, Slater EP, Carrato A, Ibrahim IS, Guillen-Ponce C, Vasen HF, Matthäi E, Earl J, Jendryschek FS, Figiel J, Steinkamp M, Ramaswamy A, Vázquez-Sequeiros E, Muñoz-Beltran M, Montans J, Mocci E, Bonsing BA, Wasser M, Klöppel G, Langer P, Fendrich V, Gress TM.

Gut. 2016 Aug;65(8):1314-21. doi: 10.1136/gutjnl-2015-311098. Epub 2016 May 24.

PMID:
27222532
33.

Pharmacological macrophage inhibition decreases metastasis formation in a genetic model of pancreatic cancer.

Griesmann H, Drexel C, Milosevic N, Sipos B, Rosendahl J, Gress TM, Michl P.

Gut. 2017 Jul;66(7):1278-1285. doi: 10.1136/gutjnl-2015-310049. Epub 2016 Mar 24.

PMID:
27013602
34.

GSK-3β Governs Inflammation-Induced NFATc2 Signaling Hubs to Promote Pancreatic Cancer Progression.

Baumgart S, Chen NM, Zhang JS, Billadeau DD, Gaisina IN, Kozikowski AP, Singh SK, Fink D, Ströbel P, Klindt C, Zhang L, Bamlet WR, Koenig A, Hessmann E, Gress TM, Ellenrieder V, Neesse A.

Mol Cancer Ther. 2016 Mar;15(3):491-502. doi: 10.1158/1535-7163.MCT-15-0309. Epub 2016 Jan 28.

35.

DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma.

Ettrich TJ, Perkhofer L, von Wichert G, Gress TM, Michl P, Hebart HF, Büchner-Steudel P, Geissler M, Muche R, Danner B, Kächele V, Berger AW, Güthle M, Seufferlein T.

BMC Cancer. 2016 Jan 15;16:21. doi: 10.1186/s12885-016-2052-4.

36.

A synthetic lethal screen identifies ATR-inhibition as a novel therapeutic approach for POLD1-deficient cancers.

Hocke S, Guo Y, Job A, Orth M, Ziesch A, Lauber K, De Toni EN, Gress TM, Herbst A, Göke B, Gallmeier E.

Oncotarget. 2016 Feb 9;7(6):7080-95. doi: 10.18632/oncotarget.6857.

37.

PLAC8 Localizes to the Inner Plasma Membrane of Pancreatic Cancer Cells and Regulates Cell Growth and Disease Progression through Critical Cell-Cycle Regulatory Pathways.

Kaistha BP, Lorenz H, Schmidt H, Sipos B, Pawlak M, Gierke B, Kreider R, Lankat-Buttgereit B, Sauer M, Fiedler L, Krattenmacher A, Geisel B, Kraus JM, Frese KK, Kelkenberg S, Giese NA, Kestler HA, Gress TM, Buchholz M.

Cancer Res. 2016 Jan 1;76(1):96-107. doi: 10.1158/0008-5472.CAN-15-0216. Epub 2015 Dec 15.

38.

Streptozocin-Based Chemotherapy in Patients with Advanced Neuroendocrine Neoplasms--Predictive and Prognostic Markers for Treatment Stratification.

Krug S, Boch M, Daniel H, Nimphius W, Müller D, Michl P, Rinke A, Gress TM.

PLoS One. 2015 Dec 2;10(12):e0143822. doi: 10.1371/journal.pone.0143822. eCollection 2015.

39.

Emerging role of microRNAs to tackle drug resistance in pancreatic cancer.

Neesse A, Gress TM.

Gut. 2015 Dec;64(12):1842-3. doi: 10.1136/gutjnl-2015-309503. Epub 2015 Jun 3. No abstract available.

PMID:
26041749
40.

Stromal biology and therapy in pancreatic cancer: a changing paradigm.

Neesse A, Algül H, Tuveson DA, Gress TM.

Gut. 2015 Sep;64(9):1476-84. doi: 10.1136/gutjnl-2015-309304. Epub 2015 May 20. Review.

PMID:
25994217
41.

A multistep high-content screening approach to identify novel functionally relevant target genes in pancreatic cancer.

Buchholz M, Honstein T, Kirchhoff S, Kreider R, Schmidt H, Sipos B, Gress TM.

PLoS One. 2015 Apr 7;10(4):e0122946. doi: 10.1371/journal.pone.0122946. eCollection 2015.

42.

Controversy on the time to progression of pancreatic ductal adenocarcinoma.

Gallmeier E, Hernaez R, Gress TM.

Gut. 2015 Nov;64(11):1676-7. doi: 10.1136/gutjnl-2014-309066. Epub 2015 Mar 2. No abstract available.

PMID:
25731873
43.

Abdominal pain following percutaneous mitral valve repair (MitraClip). Pneumatosis intestinalis (PI) of the ascending colon.

Neesse A, Nimphius W, Schoppet M, Gress TM.

Gut. 2015 Mar;64(3):458, 494. doi: 10.1136/gutjnl-2014-308495. Epub 2014 Oct 30. No abstract available.

PMID:
25360035
44.

CUX1: a modulator of tumour aggressiveness in pancreatic neuroendocrine neoplasms.

Krug S, Kühnemuth B, Griesmann H, Neesse A, Mühlberg L, Boch M, Kortenhaus J, Fendrich V, Wiese D, Sipos B, Friemel J, Gress TM, Michl P.

Endocr Relat Cancer. 2014;21(6):879-90. doi: 10.1530/ERC-14-0152. Epub 2014 Sep 23.

PMID:
25248790
45.

Paraneoplastic brainstem encephalitis in a patient with exceptionally long course of a metastasized neuroendocrine rectum neoplasm.

Boch M, Rinke A, Rexin P, Seipelt M, Brödje D, Schober M, Gress TM, Michl P, Krug S.

BMC Cancer. 2014 Sep 22;14:691. doi: 10.1186/1471-2407-14-691.

46.

In memoriam: Max G. Bachem, MD, PhD, Dr.hc Professor for Clinical Chemistry, 1952-2014.

Gress TM, Adler G, Apte M, Wilson J.

Pancreatology. 2014 Jul-Aug;14(4):231-2. No abstract available.

PMID:
25207336
47.

Key role of dual specificity kinase TTK in proliferation and survival of pancreatic cancer cells.

Kaistha BP, Honstein T, Müller V, Bielak S, Sauer M, Kreider R, Fassan M, Scarpa A, Schmees C, Volkmer H, Gress TM, Buchholz M.

Br J Cancer. 2014 Oct 28;111(9):1780-7. doi: 10.1038/bjc.2014.460. Epub 2014 Aug 19.

48.

Inflammation-induced NFATc1-STAT3 transcription complex promotes pancreatic cancer initiation by KrasG12D.

Baumgart S, Chen NM, Siveke JT, König A, Zhang JS, Singh SK, Wolf E, Bartkuhn M, Esposito I, Heßmann E, Reinecke J, Nikorowitsch J, Brunner M, Singh G, Fernandez-Zapico ME, Smyrk T, Bamlet WR, Eilers M, Neesse A, Gress TM, Billadeau DD, Tuveson D, Urrutia R, Ellenrieder V.

Cancer Discov. 2014 Jun;4(6):688-701. doi: 10.1158/2159-8290.CD-13-0593. Epub 2014 Apr 2.

49.

[A 59-year-old patient with recurrent flushes and bland hepatic cyst].

Krug S, König A, Librizzi D, Nimphius W, Gress TM, Michl P, Rinke A.

Internist (Berl). 2014 Feb;55(2):206-11. doi: 10.1007/s00108-013-3433-2. German.

PMID:
24449139
50.

Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma.

Neesse A, Krug S, Gress TM, Tuveson DA, Michl P.

Onco Targets Ther. 2013 Dec 18;7:33-43. doi: 10.2147/OTT.S38111. Review.

Supplemental Content

Loading ...
Support Center